Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
10 août 2023 16h05 HE
|
Athira Pharma, Inc.
Completed end of Phase 2 meeting and continued engagement with U.S. Food and Drug AdministrationAppointed Andrew Gengos as Chief Financial Officer and Chief Business OfficerMaintains strong balance...
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
17 juil. 2023 07h00 HE
|
Athira Pharma, Inc.
New preclinical data demonstrate neuroprotective effects of fosgonimeton in models of amyloid-ß-mediated toxicity In preclinical models, ATH-1105 protects against pathologies common to amyotrophic...
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
06 juil. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., July 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma to Participate in Upcoming June Conferences
31 mai 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
22 mai 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 22, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
11 mai 2023 16h05 HE
|
Athira Pharma, Inc.
Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease to focus on 40 mg dose Open label extension trial to be extended, providing up to 36 months of long-term exposure data...
Athira Pharma to Participate in Upcoming May Investor Conferences
08 mai 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
25 avr. 2023 16h01 HE
|
Athira Pharma, Inc.
Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer’s disease Preclinical findings with...
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
11 avr. 2023 07h00 HE
|
Athira Pharma, Inc.
Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients including improvements in measures of cognition and...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
28 mars 2023 01h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...